What to expect after first semaglutide injection is a common concern for patients beginning this GLP-1 medication for type 2 diabetes or weight management
Phase 1a studies in healthy volunteers, published in Diabetes, Obesity and Metabolism in 2023, established the compound's single-dose and multiple-dose pharmacokinetics, confirming a half-life supportive of once-daily dosing, a favorable food-effect profile, and dose-proportional exposure across the tested range
Muscle and bone loss is a common result of GLP-1 receptor agonist therapy
2 Neurodegenerative disorders 2.1 Alzheimer's disease (AD) Evidence indicates that gut microbiota composition is altered in AD, with a trend toward reduced diversity and specific bacterial taxa linked to disease severity
In 2023, GLP-1 medications represented 6.9% of annual pharmacy claims for surveyed employers